Cinfa celebrates its 10 years of presence in Kuwait with a strong commitment to health and well-being
 

(Kuwait) - The European pharmaceutical laboratory, Cinfa, recently held a gala dinner to celebrate its 10 years of presence in Kuwait. The celebration took place on February 8th at the renowned The Regency Hotel with the aim of recognizing and highlighting the arrival of Cinfa to the Kuwaiti population a decade ago. It’s commitment during all these years has been to offer a better and healthier life through access to affordable medicines with the highest quality, safety, and effectiveness.

Cinfa representatives in the region welcomed personalities from the Spanish Embassy in Kuwait, as well as doctors and pharmacists from the Kuwaiti Ministry of Health. More than 250 healthcare professionals also attended the gala, in addition to Al-Hajery & Sons and Ali Abdulwahab Al Mutawa Commercial (AAW), who play an essential role in its mission to improve people’s quality of life. In addition, the gala dinner had several representatives from Cinfa’s esteemed PharmaAccess regional partners.

Driven by life: Celebration, Commitment, and Reflection

Cinfa has worked tirelessly to provide innovative and affordable healthcare solutions, collaborating closely with healthcare professionals to understand and address their real needs.

During the gala dinner, Franc Vives, Cinfa’s Chief International Officer, has highlighted that “we have two main challenges: continue increasing market penetration and market share to bring our health solutions to more patients, and increase presence in the institutional sector”.

From its side, Julio Maset, Cinfa’s Corporate Scientific Director, has explained that “Cinfa is continuously expanding its portfolio in different health areas, but in the Gulf and specially in Kuwait, Cinfa is mainly focusing in cardiovascular and respiratory diseases, as well as pain control and antibiotics”.

And has added that “in cardiovascular, one of the main success key factors is patient compliance - to ensure that the patient will follow the medication as it has been subscribed. In pain and inflammation control, COX-2 inhibitors are one of our major overtaking, the efficacy is the same in comparison with other non-steroidal drugs, but the tolerance and safety is much better.”

Julio Maset concluded saying that “In the near future Cinfa plans to launch drugs in metabolic syndrome and diabetes control”.

Ongoing Commitment: Working For and With the Patient

Through that celebration, Cinfa recalled and shared a common goal: working for and with the patient. In this sense, the company maintains its commitment to expanding medication coverage and addressing present and future health challenges, such as the increasing longevity and prevalence of chronic conditions.

The celebration of the 10th anniversary not only has signified a milestone in Cinfa's history in Kuwait, but also has reflected its determination to continue contributing to the well-being of all.

PRINT THIS ARTICLE